Kasidy Brown,Noah I Hornick,Megan K Ruhland
Kasidy Brown
The ability of an individual's immune system to mount a productive response against the tumor is critical for the success of immunotherapy. Clinical trials in multiple tumor types have revealed that the degree and way in which any one perso...
Targeting CD24 activates macrophages to reduce tumor burden in preclinical models of solid tumors [0.03%]
靶向CD24可在实体瘤的小鼠模型中激活巨噬细胞并减少肿瘤负荷
Douglas V Faget,Rachel E Brewer,Joseane Sampaio et al.
Douglas V Faget et al.
Purpose: CD24 is a "don't eat me" signal overexpressed across multiple solid tumors and contributes to immune evasion by suppressing macrophage-mediated phagocytosis. Targeting the CD24/Siglec-10 axis represents a novel i...
Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool [0.03%]
来那度胺致多发性骨髓瘤患者腹泻与肠道微生态失调及胆汁酸紊乱相关
Kevin Charles Miller,Teng Fei,Ruben J Faustino Ramos et al.
Kevin Charles Miller et al.
Purpose: Lenalidomide is integral to multiple myeloma therapy, but long-term use is frequently complicated by diarrhea, which diminishes patient quality-of-life. The pathophysiology of lenalidomide-related diarrhea (LRD) ...
Molecular Profiling of Tisotumab Vedotin-Treated Patients Identifies Immune Pathways Associated With Clinical Activity [0.03%]
替西妥珠单抗治疗患者的分子分型确定了与临床活性相关的免疫途径
Sriram Sridhar,Guy Roukens,Christina Y Yu et al.
Sriram Sridhar et al.
Purpose: Tisotumab vedotin (TV) is a tissue factor (TF)-specific antibody-drug conjugate that was evaluated in the innovaTV 204 study in patients with recurrent or metastatic cervical cancer (r/mCC). Although TF expressio...
Targetable S100-RAGE signaling mediates intrinsic trastuzumab deruxtecan resistance in metastatic breast cancer [0.03%]
靶向S100-RAGE信号通路可介导转移性乳腺癌对曲拉西利的内在耐药性
Wenjuan Dong,Shiruo Wang,Bill Chan et al.
Wenjuan Dong et al.
Purpose: Trastuzumab deruxtecan (T-DXd) has improved outcomes in metastatic breast cancer; however, a substantial subset of patients experience early lack of clinical benefit that is not reliably predicted by routine clin...
Non-Armored GCC-targeting CAR-T cell therapy demonstrates significant efficacy in patients with advanced colorectal cancer [0.03%]
非武装GCC导向的CAR-T细胞疗法治疗晚期结直肠癌患者疗效显著
Qianyu Zhang,Lin Lin,Wei Wang et al.
Qianyu Zhang et al.
Purpose: This phase 1 clinical trial aims to evaluate the safety, expansion kinetics, and preliminary efficacy of non-armored, nanobody-derived GCC-targeted CAR-T cells in patients with heavily pretreated, metastatic colo...
Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer [0.03%]
肿瘤浸润淋巴细胞作为三阴性乳腺癌术后阿维鲁单抗疗效预测因素的研究
Maria Vittoria Dieci,Elisa Gasparini,Lorenzo Nicolè et al.
Maria Vittoria Dieci et al.
Purpose: We aimed to investigate the prognostic and predictive value of tumor infiltrating lymphocytes (TILs) for adjuvant immunotherapy in high-risk early TNBC. ...
Correction: A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas [0.03%]
纠正：多柔比星联合 zalifrelimab（抗 CTLA-4 抗体）和 balstilimab（抗 PD-1 抗体）治疗晚期/转移性软组织肉瘤 II 期单臂试验
Breelyn A Wilky,Katherine A Julian,Alessandra Maleddu et al.
Breelyn A Wilky et al.
HPV16 genomic status stratifies risk of disease recurrence in oropharyngeal squamous cell carcinoma [0.03%]
HPV16型基因组状态可对口咽鳞癌患者疾病复发风险进行分层评估
Victor Malassigné,Julien Puech,Sandrine Imbeaud et al.
Victor Malassigné et al.
Purpose: A subset of patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma develops disease recurrence despite generally favorable outcomes. Reliable biomarkers for risk stratification remain l...
Spatial Configuration of Pancreatic Cancer Is Associated with Disease Recurrence after Neoadjuvant Therapy and Curative-Intent Resection [0.03%]
新辅助治疗和根治性手术后的胰腺癌空间构型与疾病复发相关性研究
Luis H Cisneros,Merih D Toruner,Zafar Siddiqui et al.
Luis H Cisneros et al.
Purpose: Pancreatic ductal adenocarcinoma (PDAC) frequently recurs after neoadjuvant therapy (NT) and curative-intent resection. Although major pathologic response predicts favorable outcomes, most patients achieve only m...